This is the HTML version of the file http://results.ref.ac.uk/(S(b0zob4zunyoqom4nze02rgoq))/DownloadFile/ImpactCaseStudy/pdf?caseStudyId=23887. Google automatically generates HTML versions of documents as we crawl the web.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.
Impact case study (REF3b) Page 1 Institution: The University of Edinburgh Unit of Assessment: 4 Title of case study: F: Medical
Page 1
Impact case study (REF3b)
Page 1
Institution: The University of Edinburgh
Unit of Assessment: 4
Title of case study: F: Medically unexplained symptoms including chronic fatigue syndrome
can be accurately identified and treated
1. Summary of the impact (indicative maximum 100 words)
Impact: By showing the benefits of accurate identification and targeted treatment of chronic fatigue
syndrome, UoE research has influenced worldwide medical practice and stimulated public and
governmental debate.
Significance: Guidelines and policy debate have resulted in improved patient treatment, with
associated economic benefit.
Beneficiaries: Patients with medically unexplained symptoms, policy-makers, clinicians.
Attribution: Work conducted at UoE in a team led by Carson and Sharpe.
Reach: The research affects the more than 25% of all GP presentations who have unexplained
symptoms / chronic fatigue syndrome (40% in gastroenterology and neurology). Guidelines have
been changed internationally including UK, USA, Australasia.
2. Underpinning research (indicative maximum 500 words)
Up to 1 in 300 people in the UK have chronic fatigue syndrome (CFS). Moreover, more than a
quarter of all individuals presenting to a GP in the UK—in excess of 100 million consultations per
year—have pain, paralysis, bowel symptoms or chronic fatigue for which no adequate medical
explanation can be found [3.1]. These medically unexplained symptoms are also prevalent in
secondary care (e.g., neurology, where they account for more than 33% of consultations), and cost
the NHS £14K per annum per patient. The cost to the UK economy is up to £3.5B p.a. for chronic
fatigue syndrome (CFS) alone [3.2]. In spite of the considerable costs and associated suffering, the
management of these conditions has, until recently, been neglected [3.1].
Epidemiology of CFS and medically unexplained symptoms
The Edinburgh team (Professor Michael Sharpe, Professor of Psychological Medicine, UoE, 1997–
2012; now honorary Professor, University of Oxford; Dr Alan Carson, Senior Lecturer, UoE, 2011–
present; Dr Jon Stone, Honorary Clinical Senior Lecturer, UoE, 2005–present) demonstrated in
large prospective cohort studies of referrals to neurology clinics in the UK that 30% were explained
by functional ‘medically unexplained’ symptoms [3.1, 3.3]. Patients with a higher number of
individual symptoms (p<0.005) or depression (p<0.005; 70% of individuals with completely
unexplained symptoms) were more likely to be ultimately diagnosed as being without organic
disorder [3.1]. The team showed that individuals with medically unexplained symptoms had higher
mean inpatient (£3,539 difference), outpatient (£778 difference) and emergency (£99 difference)
patient costs [3.2] compared with patients presenting without these symptoms, and that their
repeated assessment had little or no benefit [3.3]. Moreover, the Edinburgh team showed that the
diagnosis of ‘medically unexplained’ was rarely changed at 18 months follow-up (0.4% of the
original sample) [3.3].
Management of individuals with medically unexplained symptoms
From 2006–2010, the Edinburgh team conducted a randomised controlled trial of guided self-help
for medically unexplained symptoms at NHS neurology clinics in Edinburgh and Glasgow. The
guided self-help was superior to the comparator treatment (odds ratio=2.36, p=0.02; number
needed to treat=8), with efficacy maintained at 6 months follow-up [3.4]. In 2011, Sharpe and
colleagues published the first definitive randomised controlled study (n=641) showing superior
efficacy of cognitive behaviour therapy (CBT) for CFS compared with specialist care alone (rating

Page 2
Impact case study (REF3b)
Page 2
scale score difference=3.4, p=0.0001), and inefficacy of the very widely recommended (at the time)
intervention of ‘pacing’ at 52 weeks follow-up (the Pacing, graded Activity and Cognitive behaviour
therapy: a randomised Evaluation (PACE) trial) [5.5]. Finally, in 2012, Edinburgh and Aarhus
Universities together published a study of CBT in a range of medically unexplained syndromes,
conducted across both primary and secondary care showing efficacy (mean difference=4.0;
p=0.002 for the primary outcome measure) over enhanced standard care [3.6].
3. References to the research (indicative maximum of six references)
3.1 Carson A, Ringbauer B, Stone J, McKenzie L, Warlow C, Sharpe M. Do medically
unexplained symptoms matter? A prospective cohort study of 300 new referrals to neurology
outpatient clinics. J Neurol Neurosurg Psychiatry. 2000;68:207–10. DOI:10.1136/jnnp.68.2.207.
3.2 Burtona C, McGorm K, Richardson G, Weller D, Sharpe M. Healthcare costs incurred by
patients repeatedly referred to secondary medical care with medically unexplained symptoms: A
cost of illness study J Psychosom Res. 2012;72:242–7. DOI: 10.1016/j.jpsychores.2011.12.009.
3.3 Stone J, Carson A, Duncan R,…Sharpe M. Symptoms ‘unexplained by organic disease’ in
1144 new neurology out-patients: how often does the diagnosis change at follow-up? Brain.
2009;132:2878–88. DOI: 10.1093/brain/awp220.
3.4 Sharpe M, Walker J, Williams C, et al. Guided self-help for functional (psychogenic)
symptoms: a randomized controlled efficacy trial. Neurology. 2011;77:564–72. DOI:
10.1212/WNL.0b013e318228c0c7.
3.5 White P, Goldsmith K, Johnson AL,…Sharpe M. Comparison of adaptive pacing therapy,
cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic
fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377:823–36. DOI: 10.1016/S0140-
6736(11)60096-2
3.6 Schröder A, Rehfeld E, Ørnbøl E, Sharpe M, Licht R, Fink P. Cognitive-behavioural group
treatment for a range of functional somatic syndromes: randomised trial. Br J Psychiatry.
2012;200:499–507. DOI: 10.1192/bjp.bp.111.098681.
4. Details of the impact (indicative maximum 750 words)
The UoE work challenged the once popularly held view that 1. CFS is an organic disorder for which
assessment and treatment are inappropriate or ineffective; 2. ‘functional’ neurological symptoms
are often eventually explained by organic disease; and 3. functional ‘medically unexplained’
symptoms are completely explained by life events, are often short-lived and the patients can be
neither engaged nor treated.
Pathways to impact
The work has been presented at international meetings, and published in high-impact medical
journals with global reach accompanied by UoE and Medical Research Council press releases and
by extensive commentaries on the importance of the research on the websites of the funding
bodies (e.g., http://www.mrc.ac.uk/Newspublications/News/MRC007706, Feb 2011).
Impact on public policy and clinical practice
The UoE research has led to changes in national and international guidelines on the management
of medically unexplained symptoms and CFS/myalgic encephalomyelitis (ME), e.g., in the UK
(Chief Scientist Office guidance on CFS was endorsed by The Royal College of General
Practitioners in 2010), the USA [5.1] and Australia [5.2]. Professor Sharpe was on the guideline
working group for the USA guidelines.
The work has also led specifically to individual service developments across the UK (e.g.,

Page 3
Impact case study (REF3b)
Page 3
Yorkshire [5.3], Lothians (2008), Oxford (2013) and Nottingham (2011)), and directly to changes in
what is considered best clinical practice [5.4].
The work has fed into the development of the International Classification of Diseases (ICD-11) and
the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-V) [5.5].
Reference has been made to the UoE research in both the House of Commons and the House of
Lords, which has led to political pressure to provide better services for people with medically
unexplained symptoms (e.g., House of Commons Early Day Motion 405, July 2010 [5.6]).
Impact on public engagement
Edinburgh work on CFS and medically unexplained symptoms has been widely disseminated to
the public, for instance by coverage on national and international news (e.g., BBC news, Feb 2011
[5.7]; USA National Public Radio broadcast by R Knox, Feb 2011; ABC News Australia, Aug 2012)
and articles on the websites of patient organisations [e.g., 5.8].
The Edinburgh group also set up a website for the community of individuals with medically
unexplained symptoms (http://www.neurosymptoms.org). This site receives an average of 30,000
hits per month; it has had 466,061 unique hits since its creation in 2009 and has been translated
by neurologists into 10 languages. It is widely used by clinicians and the public in the USA (41% of
hits) and UK (38% of hits), and is linked from the Movement Disorders Society, Royal College of
Psychiatrists and MS Society websites, in addition to the BBC.
Impact on the economy
CFS costs the NHS £14K per annum per patient and the annual cost to the UK economy is up to
£3.5B [3.2]. It is clear that enormous savings can be made by effective management of this
condition.
A Dutch study suggested that up to 3.6% of the workforce suffers from CFS. The UoE research
has led to national changes in the occupational management of individuals with medically
unexplained symptoms, demonstrating effective strategies to reduce absence from work (e.g.,
NHS/Royal College of Physicians Guidance [5.9]).
5. Sources to corroborate the impact (indicative maximum of 10 references)
5.1 US Department of Veterans Affairs. VA/DoD clinical practice guidelines for the management
of medically unexplained symptoms: chronic pain and fatigue (2002).
http://www.healthquality.va.gov/mus/mus_fulltext.pdf. [USA guidelines. N.B. These remain the
current guidelines from 2008–present.]
5.2 Government of South Australia. A guideline for the diagnosis and management of ME/CFS in
the community or primary care setting. Management guidelines for General Practitioners (2004);
http://sacfs.asn.au/download/guidelines.pdf [Australian guidelines. N.B. These remain the current
guidelines from 2008–present].
5.3 Leeds & West Yorkshire CFS/ME service.
http://www.bacme.info/document_uploads/POD_Docs/MancfsinPrimCare.pdf [Corroborates
establishment of specialist CFS/ME services.]
5.4
Scottish Good Practice Statement on ME-CFS (2010)
http://www.show.scot.nhs.uk/App_Shared/docs/MainDoc.pdf. [Corroborates change to clinical
practice regarding CFS/ME.]
5.5 APA DSM-5 Work Group Member Disclosure Report (2012).
http://www.dsm5.org/MeetUs/Documents/Somatic%202012/Sharpe-Disclosure-2012.pdf.
[Corroborates Sharpe’s membership of Somatic Distress DSM-V Work Group.]

Page 4
Impact case study (REF3b)
Page 4
5.6 House of Commons Early Day Motion on Chronic Fatigue Syndrome / Myalgic
Encephalomyelitis (2010). http://www.parliament.uk/edm/2010-12/405. [Corroborates debate of
CFS/ME in the House of Commons.]
5.7 “Brain and body training treats ME, UK study says” (2011).
http://www.bbc.co.uk/news/health-12493009. [BBC news coverage of clinical trials contributing to
public engagement.]
5.8 “Professor Sharpe and Richard Horton talk about the PACE trial on ABC National Radio,
Australia: 18 April 2011”. Article on UK ME Association website (2011):
http://www.meassociation.org.uk/?p=5703. [Article on patient website contributing to public
engagement.]
5.9 NHS Plus. Occupational Aspects of the Management of Chronic Fatigue Syndrome: a
National Guideline (2006).
http://www.anhops.com/docs/92_8_273539_CFSyndrome_full_review.pdf. [Evidence that the
research has altered guidelines for occupational management. N.B. These remain the current
guidelines from 2008–present.]